熊去氧胆酸对不同原因胆汁淤积性肝病患者鼻胆管引流术后胆汁排泌的影响

李磊; 李冰; 丁惠国

doi:10.3969/j.issn.1001-5256.2016.03.026

熊去氧胆酸对不同原因胆汁淤积性肝病患者鼻胆管引流术后胆汁排泌的影响

DOI: 10.3969/j.issn.1001-5256.2016.03.026

首都医科大学附属北京佑安医院消化中心

基金项目:

北京市卫生系统高层次卫生技术人才(2013-03-073)；首都医学发展专项(2011-4022-06)；

详细信息

中图分类号: R575
计量
- 文章访问数: 2038
- HTML全文浏览量: 13
- PDF下载量: 399
- 被引次数: 0
出版历程
- 出版日期: 2016-03-20

Effect of ursodeoxycholic acid on bile secretion after endoscopic nasobiliary drainage in patients with cholestatic liver disease of various causes

Department of Gastroenterology and Hepatology, Beijing You′an Hospital Affiliated to Capital Medical University

Research funding:

摘要

摘要:
目的观察熊去氧胆酸（UDCA）对不同原因胆汁淤积性肝病患者胆汁排泌的影响。方法收集2013年7月-2014年5月于首都医科大学附属北京佑安医院接受鼻胆管引流术患者48例,分为UDCA治疗组（36例）和对照组（12例）,UDCA治疗组根据病因再分为胆总管结石组（9例）、胆管癌组（7例）、硬化性胆管炎组（7例）、肝移植术后组（13例）。UDCA治疗组患者于术后第2天开始口服UDCA胶囊（250 mg,3次/d）,记录术后7 d每日胆汁引流量,于术前1天、术后第7天检测血清TBil、总胆汁酸（TBA）、GGT、ALP水平,比较UDCA对胆汁引流量、TBil、TBA、GGT、ALP的影响。计量资料两组间比较采用t检验,多组间比较采用方差分析;计数资料组间比较采用χ2检验。结果与对照组相比,UDCA治疗组胆汁引流量术后第3、4、5天明显增多,差异均有统计学意义（t值分别为2.461、3.896、2.760,P值分别为0.048、0.021、0.034）,其中胆总管结石、胆管癌和肝移植术后3组患者胆汁引流量增加较明显,均在术后第4天呈现高峰;与术前1天相比,术后第7天胆总管结石和肝移植术后2组患者...
- 肝疾病 /
- 胆汁淤积 /
- 熊脱氧胆酸 /
- 引流术
Abstract:
Objective To observe the effect of ursodeoxycholic acid( UDCA) on bile secretion in patients with cholestatic liver disease of various causes. Methods A total of 48 patients who underwent endoscopic nasobiliary drainage( ENBD) in Beijing You'an Hospital Affiliated to Capital Medical University from July 2013 to May 2014 were enrolled and divided into UDCA treatment group( n = 36) and control group( n = 12). The patients in the UDCA group were further divided into common bile duct stone group( n = 9),cholangiocarcinoma group( n = 7),sclerosing cholangitis group( n = 7),and post- liver transplantation group( n = 13). The patients in the UDCA treatment group received oral UDCA capsules( 250 mg,3 times / day) since the second day after surgery,and the daily volume of bile drainage was recorded for 7 days after surgery. Serum levels of total bilirubin( TBil),total bile acid( TBA),gamma- glutamyl transpeptidase( GGT),and alkaline phosphatase( ALP) were measured on the day before surgery and the 7th day after surgery,and the effects of UDCA on volume of bile drainage,TBil,TBA,GGT,and ALP were compared between groups. The t- test was applied for comparison between groups,comparison of continuous data between these groups was made by analysis of variance; the chi- square test was applied for comparison of categorical data between groups. Results Compared with the control group,the UDCA treatment group had a significantly increased volume of bile drainage on the 3rd,4th,and 5th days after surgery( t = 2. 461,3. 896,and 2.760; P = 0. 048,0. 021,and 0. 034),and the increase in volume of bile drainage was more significant in the common bile duct stone group,the cholangiocarcinoma group,and the post- liver transplantation group,with peak values appearing on the 4th day after surgery. The patients in the common bile duct stone group and the post- liver transplantation group had significantly lower serum levels of TBil,GGT,and ALP on the 7th day after surgery( t = 3. 340,2. 503,and 2. 158,P = 0. 016,0. 038,and 0. 045; t = 2. 951,2. 805,and 2. 461,P = 0. 014,0. 029,and 0. 034). Conclusion UDCA can increase bile secretion and improve liver function in patients with cholestatic liver disease of various causes.
- liver diseases /
- cholestasis /
- ursodeoxycholic acid /
- drainage

HTML全文

参考文献(14)

[1]HOSONUMA K,SATO K,YAMAZAKI Y,et al.A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia[J].Am J Gastroenterol,2015,110(3):423-431.

[2]CZUL F,PEYTON A,LEVY C.Primary biliary cirrhosis:therapeutic advances[J].Clin Liver Dis,2013,17(2):229-242.

[3]GIANTURCO V,TROISI G,BELLOMO A,et al.Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease:double-blind,randomized clinical trial of efficacy and safety[J].Hepatol Int,2013,7(2):570-576.

[4]MOUSA HS,LEO A,INVEMIZZI P,et al.Advances in pharmacotherapy for primary biliary cirrhosis[J].Expert Opin Pharmacother,2015,16(5):633-643.

[5]POUPON R.Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases:an overview of their mechanisms of action[J].Clin Res Hepatol Gastroenterol,2012,36(Suppl 1):s3-s12.

[6]BEUERS U,TRAUNER M,JANSEN P,et al.New paradigms in the treatment of hepatic cholestasis:from UDCA to FXR,PXR and beyond[J].J Hepatol,2015,62(1 Suppl):s25-s37.

[7]LIU C,XU CY,LI GD,et al.Analysis of clinical features of patients with autoimmune hepatitis/primary biliary cirrhoss overlap syndrome[J].J Jilin Univ:Med Edit,2014,40(3):646-649.(in Chinese)刘晨,徐长妍,李国东,等.自身免疫性肝炎/原发性胆汁性肝硬化重叠综合征患者临床特征分析[J].吉林大学学报:医学版,2014,40(3):646-649.

[8]EATON JE,TALWALKAR JA,LAZARIDIS KN,et al.Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management[J].Gastroenterology,2013,145(3):521-536.

[9]CROSIGNANI A,BATTEZZATI PM,INVEMIZZI P,et al.Clinical features and management of primary biliary cirrhosis[J].World J Gastroenterol,2008,14(21):3313-3327.

[10]JOUTSINIEMI T,TIMONEN S,LINDEN M,et al.Intrahepatic cholestasis of pregnancy:observational study of the treatment with low-dose ursodeoxycholic acid[J].BMC Gastroenterol,2015,15(1):92.

[11]WANG SY,TANG MH,CHEN GQ,et al.Effect of post-liver transplantation administration of ursodeoxycholic acid on serum liver tests and biliary complications:a randomized clinical trial[J].Chin J Hepatol,2014,22(7):529-535.(in Chinese)王书云,唐美华,陈国庆,等.肝移植后熊去氧胆酸对肝生物化学指标及胆管并发症影响的临床随机对照研究[J].中华肝脏病杂志,2014,22(7):529-535.

[12]HIGUERA-de-la TIJERA F,SERVIN-CAAMANO AI.Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets[J].World J Hepatol,2015,7(10):1297-1301.

[13]XIANG Z,CHEN YP,MA KF,et al.The role of ursodeoxycholic acid in non-alcoholic steatohepatitis:a systematic review[J].BMC Gastroenterol,2013,13:140.

[14]ZHOU XY,TIAN YZ.The recent advances in the treatment of refractory primary biliary cirrhosis[J].Jilin J Tradit Chin Med,2014,34(11):1185-1188.(in Chinese)周新源,田耀洲.难治性原发性胆汁性肝硬化治疗进展[J].吉林中医药,2014,34(11):1185-1188.

施引文献

资源附件(0)

访问统计